|Systematic (IUPAC) name|
|Trade names||Acetadote, Fluimucil, Mucomyst, Parvolex|
|Licence data||US Daily Med:|
|Oral, injection, inhalation|
|Excretion||Renal (22%), faecal (3%)|
|R05 S01 V03|
|Melting point||106 °C (223 °F)|
|Boiling point||108 °C (226 °F)|
|200 mg/mL (20 °C)|
|(what is this?)|
Acetylcysteine rINN //, also known as N-acetylcysteine or N-acetyl-L-cysteine (abbreviated NAC), is a pharmaceutical drug and nutritional supplement used primarily as a mucolytic agent and in the management of paracetamol (acetaminophen) overdose. Other uses include sulfate repletion in conditions, such as autism, where cysteine and related sulfur amino acids may be depleted.
Acetylcysteine is a derivative of cysteine where an acetyl group is attached to the nitrogen atom. This compound is sold as a dietary supplement commonly claiming antioxidant and liver protecting effects. It is used as a cough medicine because it breaks disulfide bonds in mucus and liquefies it, making it easier to cough up. It is also this action of breaking disulfide bonds that makes it useful in thinning the abnormally thick mucus in cystic and pulmonary fibrosis patients.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
- 1 Medical uses
- 2 Adverse effects
- 3 Pharmacology
- 4 Complexing agent
- 5 Chemistry
- 6 Dosage forms
- 7 Research
- 8 References
- 9 External links
Intravenous and oral formulations of acetylcysteine are available for the treatment of paracetamol (acetaminophen) overdose. When paracetamol is taken in large quantities, a minor metabolite called N-acetyl-p-benzoquinone imine (NAPQI) accumulates within the body. It is normally conjugated by glutathione, but when taken in excess, the body's glutathione reserves are not sufficient to inactivate the toxic NAPQI. This metabolite is then free to react with key hepatic enzymes, thereby damaging hepatocytes. This may lead to severe liver damage and even death by acute liver failure.
In the treatment of acetaminophen overdose, acetylcysteine acts to maintain or replenish depleted glutathione reserves in the liver and enhance non-toxic metabolism of acetaminophen. These actions serve to protect hepatocytes in the liver from NAPQI toxicity. It is most effective in preventing or lessening hepatic injury when administered within 8–10 hours after overdose. Research suggests that the rate of hepatotoxicity is approximately 3% when acetylcysteine is administered within 10 hours of overdose.
Although both IV and oral acetylcysteine are equally effective for this indication, oral administration is poorly tolerated because high oral doses are required due to low oral bioavailability, because of its very unpleasant taste and odour, and because of adverse effects, particularly nausea and vomiting. Prior pharmacokinetic studies of acetylcysteine did not consider acetylation as a reason for the low bioavailability of acetylcysteine. Oral acetylcysteine is identical in bioavailability to cysteine precursors. However, 3% to 6% of people given intravenous acetylcysteine show a severe, anaphylaxis-like allergic reaction, which may include extreme breathing difficulty (due to bronchospasm), a decrease in blood pressure, rash, angioedema, and sometimes also nausea and vomiting. Repeated doses of intravenous acetylcysteine will cause these allergic reactions to progressively worsen in these people.
Several studies have found this anaphylaxis-like reaction to occur more often in people given IV acetylcysteine despite serum levels of paracetamol not high enough to be considered toxic. In some countries, a specific intravenous formulation does not exist to treat paracetamol overdose. In these cases, the formulation used for inhalation may be used intravenously.
Inhaled acetylcysteine is indicated for mucolytic ("mucus-dissolving") therapy as an adjuvant in respiratory conditions with excessive and/or thick mucus production. Such conditions include emphysema, bronchitis, tuberculosis, bronchiectasis, amyloidosis, pneumonia, cystic fibrosis, chronic obstructive pulmonary disease, and pulmonary fibrosis. It is also used post-operatively, as a diagnostic aid, and in tracheotomy care. It may be considered ineffective in cystic fibrosis. However, a recent paper in the Proceedings of the National Academy of Sciences reports that high-dose oral acetylcysteine modulates inflammation in cystic fibrosis and has the potential to counter the intertwined redox and inflammatory imbalances in CF. Oral acetylcysteine may also be used as a mucolytic in less serious cases.
For this indication, acetylcysteine acts to reduce mucus viscosity by splitting disulfide bonds linking proteins present in the mucus (mucoproteins). Furthermore, with respect to its use as a mucolytic agent in patients with COPD, it is hypothesized that acetylcysteine may exert additional beneficial effects through its anti-inflammatory and antioxidant properties.
Oral acetylcysteine is used for the prevention of radiocontrast-induced nephropathy (a form of acute renal failure). Some studies show that prior administration of acetylcysteine markedly decreases radiocontrast nephropathy, whereas others appear to cast doubt on its efficacy. It has been concluded that
- "Intravenous and oral N-acetylcysteine may prevent contrast-medium–induced nephropathy with a dose-dependent effect in patients treated with primary angioplasty and may improve hospital outcome."
- "Acetylcysteine protects patients with moderate chronic renal insufficiency from contrast-induced deterioration in renal function after coronary angiographic procedures, with minimal adverse effects and at a low cost"
A clinical trial from 2010, however, found that acetylcysteine is ineffective for the prevention of contrast-induced nephropathy. This trial, involving 2,308 patients, found that acetylcysteine was no better than a placebo; whether acetylcysteine or the placebo was used, the incidence of nephropathy was the same — 13%.
Despite the conflicting research outcomes, the 2012 Kidney Disease: Improving Global Outcomes Guidelines suggest the use of oral acetylcysteine for the prevention of contrast-induced nephropathy in high-risk individuals, given its potential for benefit, low likelihood of adverse effects, and low cost.
Cyclophosphamide-induced hemorrhagic cystitis
Acetylcysteine has been used for cyclophosphamide-induced hemorrhagic cystitis, although mesna is generally preferred due to the ability of acetylcysteine to diminish the effectiveness of cyclophosphamide.
Acetylcysteine can be used in Petroff's method i.e. liquefaction and decontamination of sputum, in preparation for recovery of mycobacterium. It also displays significant antiviral activity against the influenza A viruses.
Acetylcysteine has bactericidal properties and breaks down bacterial biofilms of clinically relevant pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Enterobacter cloacae, Staphylococcus epidermidis and Klebsiella pneumoniae.
Interstitial lung disease
Acetylcysteine has been successfully tried as a treatment for a number of psychiatric disorders. In particular, as a treatment for schizophrenia, bipolar disorder, trichotillomania, skin picking, autism, obsessive-compulsive disorder, drug (including nicotine, cannabis, methamphetamine, cocaine, etc.) and gambling addiction.
Acetylcysteine has also been hypothesized to exert beneficial effects through its modulation of glutamate and dopamine neurotransmission as well as its antioxidant properties. NAC has also been trialled with some efficacy in people with Alzheimer disease.
The most commonly reported adverse effects for IV formulations of acetylcysteine are rash, urticaria, and pruritis. Up to 18% of patients have been reported to experience anaphylactoid reactions, which are defined as rash, hypotension, wheezing, and/or shortness of breath. Lower rates of anaphylactoid reactions have been reported with slower rates of infusion.
Adverse effects for inhalational formulations of acetylcysteine include nausea, vomiting, stomatitis, fever, rhinorrhea, drowsiness, clamminess, chest tightness, and bronchoconstriction. Through infrequent, bronchospasm has been reported to occur unpredictably in some patients.
Adverse effects for oral formulations of acetylcysteine have been reported to include nausea, vomiting, rash, and fever.
Antioxidants are widely used to protect cells from damage induced by reactive oxygen species (ROS). The concept that antioxidants can help fight cancer is deeply rooted in the general population, promoted by the food supplement industry, and supported by some scientific studies. However, clinical trials have reported inconsistent results. Supplementing the diet with the antioxidants N-acetylcysteine (NAC) and vitamin E markedly increased tumor progression and reduced survival in mouse models of B-RAF and K-RAS induced lung cancer. RNA sequencing revealed that NAC and vitamin E, which are structurally unrelated, produce highly coordinated changes in tumor transcriptome profiles, dominated by reduced expression of endogenous antioxidant genes. NAC and vitamin E increase tumor cell proliferation by reducing ROS, DNA damage, and p53 expression in mouse and human lung tumor cells. High levels of ROS or prolonged stress upregulates p53 and provokes a pro-oxidant response to further increase ROS, which subsequently elicits the p53-dependent apoptotic processes to eliminate damaged cells. Thus, antioxidants can accelerate tumor growth by disrupting the ROS-p53 axis apoptosis, and autophagy, processes. Because somatic mutations in p53 occur late in tumor progression, antioxidants may accelerate the growth of early tumors or precancerous lesions in high-risk populations such as smokers and patients with chronic obstructive pulmonary disease who receive NAC to relieve mucus production. It is not clear what dose(s) induced these effects. Additionally, it is important to reiterate that NAC does not cause cancer, it counteracts ROS accumulation caused by p53 and down-regulates p53, which in turn prevents p53-induced apoptosis and promotes autophagy. in all cells; it is a dose dependent response, and the ability to manipulate cellular apoptosis and autophagy has many therapeutic benefits. Large doses in a mouse model that acetylcysteine could potentially cause damage to the heart and lungs. They found that acetylcysteine was metabolized to S-nitroso-N-acetylcysteine (SNOAC), which increased blood pressure in the lungs and right ventricle of the heart (pulmonary artery hypertension) in mice treated with acetylcysteine. The effect was similar to that observed following a 3-week exposure to an oxygen-deprived environment (chronic hypoxia). The authors also found that SNOAC induced a hypoxia-like response in the expression of several important genes both in vitro and in vivo.
The implications of these findings for long-term treatment with acetylcysteine have not yet been investigated. The dose used by Palmer and colleagues was dramatically higher than that used in humans, the equivalent of about 20 grams per day. Nonetheless, positive effects on age-diminished control of respiration (the hypoxic ventilatory response) have been observed previously in human subjects at more moderate doses.
Although N-acetylcysteine prevented liver damage when taken before alcohol, when taken 4 hours after alcohol it actually made liver damage worse in a dose-dependent fashion.
Acetylcysteine serves as a prodrug to L-cysteine which is a precursor to the biologic antioxidant, glutathione and hence administration of acetylcysteine replenishes glutathione stores. L-cysteine also serves as a precursor to cystine which in turn serves as a substrate for the cystine-glutamate antiporter on astrocytes hence increasing glutamate release into the extracellular space. This glutamate in turn acts on mGluR2/3 receptors, and at higher doses of acetylcysteine, mGluR5. Glutathione also modulates the NMDA receptor by acting at the redox site. Acetylcysteine also possesses some anti-inflammatory effects possibly via inhibiting NF-κB and modulating cytokine synthesis.
Extensively liver metabolized; CYP450 minimal. Urine excretion 22-30% with a half-life of 5.6 hours in adults and 11 hours in neonates.
Acetylcysteine is the N-acetyl derivative of the amino acid L-cysteine, and is a precursor in the formation of the antioxidant glutathione in the body. The thiol (sulfhydryl) group confers antioxidant effects and is able to reduce free radicals.
N-acetyl-L-cysteine is soluble 1 in 8 of water and 1 in 2 of ethanol. It is practically insoluble in chloroform and ether. Sigma has dissolved this product in water at 100 mg/mL with heating and obtained a clear, colorless solution.
Appearance: White to white with light yellow cast powder Melting Point: 109 - 110 ° C pKa: 9.5 at 30 ° C Optical rotation: +5 ° (c = 3% in water) 
Acetylcysteine is available in different dosage forms for different indications:
- Solution for inhalation (Assist, Mucomyst, Mucosil) – inhaled for mucolytic therapy or ingested for nephroprotective effect (kidney protection)
- IV injection (Assist,Parvolex, Acetadote) – treatment of paracetamol/acetaminophen overdose
- Oral solution – various indications.
- Effervescent Tablets (200 mg)
- Ocular solution - for mucolytic therapy
The IV injection and inhalation preparations are, in general, prescription only, whereas the oral solution and the effervescent tablets are available over the counter in many countries. Acetylcysteine is available as a health supplement in the United States, typically in capsule form.
- There is some evidence that acetylcysteine may be useful in traumatic brain injury. Trials in humans; however, have not been reported as of 2014.
- It has been suggested that acetylcysteine may help sufferers of Samter's triad by increasing levels of glutathione allowing faster breakdown of salicylates, though there is no evidence that it is of benefit.
- It has been shown to help women with PCOS (polycystic ovary syndrome) to reduce insulin problems and possibly improve fertility.
- Small studies have shown acetylcysteine to be of benefit to sufferers of blepharitis. and has been shown to reduce ocular soreness caused by Sjogren's syndrome.
- It has been shown effective in the treatment of Unverricht-Lundborg disease in an open trial in 4 patients. A marked decrease in myoclonus and some normalization of somatosensory evoked potentials with acetylcysteine treatment has been documented.
- The effect of acetylcysteine in combination with glucocorticoids (combination group) for patients suffering from severe alcoholic hepatitis was examined and showed that the combination of acetylcysteine with prednisolone decreased mortality significantly at one month compared to the prednisolone-only group (8% vs 24%, P=0.006). However, the improvement was not as significant at 3 months or 6 months (22% vs 34%, P=0.06) and (27% vs 38%, P=0.07). Factors that were associated with increased 6-month survival included younger age, shorter prothrombin time, lower levels of bilirubin in baseline studies, and decrease in bilirubin on day 14, all (P<0.001). Death due to hepatorenal syndrome occurred less frequently for the combination group at 6 months (9% vs 22%, P=0.02) and infections were also less frequent in the combination group as well (P=0.001). Six-month survival, the primary outcome, was not improved in conclusion.
- Acetylcysteine has been hypothesized to be beneficial in Parkinson's disease. It is currently undergoing clinical trials.
- It has been demonstrated to improve the volume, motility, and viscosity of semen, and may improve male fertility.
- "L-Cysteine, N-acetyl- - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 25 March 2005. Identification. Retrieved 9 January 2012.
- "ACETYLCYSTEINE solution [Fresenius Kabi USA, LLC]". DailyMed. Fresenius Kabi USA, LLC. September 2013. Retrieved 8 November 2013.
- "ACETADOTE (acetylcysteine) injection, solution [Cumberland Pharmaceuticals Inc.]". DailyMed. Cumberland Pharmaceuticals Inc. June 2013. Retrieved 8 November 2013.
- Acetylcysteine. Martindale: The Complete Drug Reference (The Royal Pharmaceutical Society of Great Britain). 16 November 2012. Retrieved 8 November 2013.
- "PRODUCT INFORMATION ACETADOTE® CONCENTRATED INJECTION" (PDF). TGA eBusiness Services. Phebra Pty Ltd. 16 January 2013. Retrieved 8 November 2013.
- Borgström L, Kågedal B, Paulsen O (1986). "Pharmacokinetics of N-acetylcysteine in man". Eur. J. Clin. Pharmacol. 31 (2): 217–22. doi:10.1007/BF00606662. PMID 3803419.
- Geier DA, Geier MR (2006). "A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders". Horm. Res. 66 (4): 182–8. doi:10.1159/000094467. PMID 16825783.
- "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
- Green, JL; Heard, KJ, Reynolds, KM, Albert, D (May 2013). "Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis". West J Emerg Med 3: 218–26. doi:10.5811/westjem.2012.4.6885. PMC 3656701. PMID 23687539.
- "Acetadote Package Insert". FDA. Retrieved 19 April 2014.
- Dilger RN, Baker DH (2007). "Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine". J. Anim. Sci. 85 (7): 1712–8. doi:10.2527/jas.2006-835. PMID 17371789.
- Kanter MZ (2006). "Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning". Am J Health Syst Pharm 63 (19): 1821–7. doi:10.2146/ajhp060050. PMID 16990628.
- Dawson AH, Henry DA, McEwen J (1989). "Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning". Med. J. Aust. 150 (6): 329–31. PMID 2716644.
- Bailey B, McGuigan MA (1998). "Management of anaphylactoid reactions to intravenous N-acetylcysteine". Ann Emerg Med 31 (6): 710–5. doi:10.1016/S0196-0644(98)70229-X. PMID 9624310.
- Schmidt LE, Dalhoff K (2001). "Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning". Br J Clin Pharmacol 51 (1): 87–91. doi:10.1046/j.1365-2125.2001.01305.x. PMC 2014432. PMID 11167669.
- Lynch RM, Robertson R (2004). "Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study". Accid Emerg Nurs 12 (1): 10–5. doi:10.1016/j.aaen.2003.07.001. PMID 14700565.
- Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
- Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA (2006). "High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis". Proc. Natl. Acad. Sci. U.S.A. 103 (12): 4628–33. doi:10.1073/pnas.0511304103. PMC 1450222. PMID 16537378.
- Tse, HN; Raiteri, L; Wong, K. Y; Yee, K. S et al. (2013). "High-dose N-acetylcysteine in stable COPD: The 1-year, double-blind, randomized, placebo-controlled HIACE study". Chest 144 (1): 106–118. doi:10.1378/chest.12-2357. PMID 23348146.
- Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000). "Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine". N. Engl. J. Med. 343 (3): 180–4. doi:10.1056/NEJM200007203430304. PMID 10900277.
- Hoffmann U, Fischereder M, Krüger B, Drobnik W, Krämer BK (2004). "The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable". J. Am. Soc. Nephrol. 15 (2): 407–10. doi:10.1097/01.ASN.0000106780.14856.55. PMID 14747387.
- Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, Seidelin P, Daly P, Ross J, McLaughlin PR, Ing D, Lewycky P, Barolet A, Schwartz L (2004). "N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up". Am. Heart J. 148 (4): 690–5. doi:10.1016/j.ahj.2004.05.015. PMID 15459602.
- Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL (2006). "N-acetylcysteine and contrast-induced nephropathy in primary angioplasty". N. Engl. J. Med. 354 (26): 2773–82. doi:10.1056/NEJMoa054209. PMID 16807414.
- Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF (2003). "Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial". JAMA 289 (5): 553–8. doi:10.1001/jama.289.5.553. PMID 12578487.
- "Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT)". Circulation 124 (11): 1250–9. 2011. doi:10.1161/CIRCULATIONAHA.111.038943. PMID 21859972.
- Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. "KDIGO Clinical Practice Guideline for Acute Kidney Injury". Retrieved 19 April 2014.
- Palma PC, Villaça Júnior CJ, Netto Júnior NR (1986). "N-acetylcysteine in the prevention of cyclophosphamide induced haemorrhagic cystitis". Int Surg 71 (1): 36–7. PMID 3522468.
- Hemorrhagic Cystitis Treatment & Management http://emedicine.medscape.com/article/2056130-treatment#aw2aab6b5b4
- Buijtels, PC; Petit, PL (2005). "Comparison of NaOH-N-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens". Journal of Microbiological Methods 62 (1): 83–88. doi:10.1016/j.mimet.2005.01.010. PMID 15823396.
- Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J (2010). "N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus". Biochem. Pharmacol. 79 (3): 413–20. doi:10.1016/j.bcp.2009.08.025. PMID 19732754.
- Aslam, S; Darouiche, R. O. (2011). "Role of antibiofilm-antimicrobial agents in controlling device-related infections". The International Journal of Artificial Organs 34 (9): 752–8. doi:10.5301/ijao.5000024. PMC 3251652. PMID 22094553.
- Grandjean EM, Berthet P, Ruffmann R, Leuenberger P (2000). "Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials". Clin Ther 22 (2): 209–21. doi:10.1016/S0149-2918(00)88479-9. PMID 10743980.
- Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR (2000). "The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review". Eur. Respir. J. 16 (2): 253–62. doi:10.1034/j.1399-3003.2000.16b12.x. PMID 10968500.
- Poole PJ, Black PN (2001). "Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review". BMJ 322 (7297): 1271–4. doi:10.1136/bmj.322.7297.1271. PMC 31920. PMID 11375228.
- Dean, O; Giorlando, F; Berk, M (Mar 2011). "N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.". Journal of psychiatry & neuroscience : JPN 36 (2): 78–86. doi:10.1503/jpn.100057. PMC 3044191. PMID 21118657.
- Berk M, Malhi GS, Gray LJ, Dean OM (2013). "The promise of N-acetylcysteine in neuropsychiatry". Trends Pharmacol. Sci. 34 (3): 167–77. doi:10.1016/j.tips.2013.01.001. PMID 23369637.
- Bavarsad Shahripour, R.; Harrigan, M. R.; Alexandrov, A. V. (2014). "N-acetylcysteine (NAC) in neurological disorders: Mechanisms of action and therapeutic opportunities". Brain and Behavior 4 (2): 108–22. doi:10.1002/brb3.208. PMC 3967529. PMID 24683506.
- Berk, M; Malhi, GS; Gray, LJ; Dean, OM (May 2013). "The promise of N-acetylcysteine in neuropsychiatry.". Trends in Pharmacological Sciences 34 (3): 167–77. doi:10.1016/j.tips.2013.01.001. PMID 23369637.
- Samuni, Y; Goldstein, S; Dean, OM; Berk, M (August 2013). "The chemistry and biological activities of N-acetylcysteine.". Biochimica et Biophysica Acta 1830 (8): 4117–29. doi:10.1016/j.bbagen.2013.04.016. PMID 23618697.
- Berk, M; Malhi, GS, Gray, LJ, Dean, OM (2013). "The promise of N-acetylcysteine in neuropsychiatry". Trends in Pharmacological Sciences 34 (3): 167–177. doi:10.1016/j.tips.2013.01.001. PMID 23369637.
- "Mucomyst Package Insert". Retrieved 20 April 2014.
- Bjelakovic G, Nikolova D, Gluud C (2013). "Antioxidant supplements to prevent mortality". JAMA 310 (11): 1178–9. doi:10.1001/jama.2013.277028. PMID 24045742.
- Chen W, Jiang T, Wang H, Tao S, Lau A, Fang D, Zhang DD (2012). "Does Nrf2 contribute to p53-mediated control of cell survival and death?". Antioxid. Redox Signal. 17 (12): 1670–5. doi:10.1089/ars.2012.4674. PMC 3474188. PMID 22559194.
- Bensaad K, Vousden KH (2005). "Savior and slayer: the two faces of p53". Nat. Med. 11 (12): 1278–9. doi:10.1038/nm1205-1278. PMID 16333263.
- Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T, Cimino F (2006). "p53 suppresses the Nrf2-dependent transcription of antioxidant response genes". J. Biol. Chem. 281 (52): 39776–84. doi:10.1074/jbc.M605707200. PMID 17077087.
- Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO (2014). "Antioxidants accelerate lung cancer progression in mice". Sci Transl Med 6 (221): 221ra15. doi:10.1126/scitranslmed.3007653. PMID 24477002.
- Sablina A A, Budanov A V, Ilyinskaya G V, Agapova L S, Kravchenko J E, Chumakov P M (2005). "The antioxidant function of the p53 tumor suppressor". Nature Medicine 11 (12): 1306–1313. doi:10.1038/nm1320. PMID 16286925.
- Merenlender-Wagner A, Malishkevich A, Shemer Z, Udawela M, Gibbons A, Scarr E, Dean B, Levine J, Agam G, Gozes I (2013). "Autophagy has a key role in the pathophysiology of schizophrenia". Mol. Psychiatry. doi:10.1038/mp.2013.174. PMID 24365867.
- Li J, Ghiani CA, Kim JY, Liu A, Sandoval J, DeVellis J, Casaccia-Bonnefil P (2008). "Inhibition of p53 transcriptional activity: a potential target for future development of therapeutic strategies for primary demyelination". J. Neurosci. 28 (24): 6118–27. doi:10.1523/JNEUROSCI.0184-08.2008. PMC 2962898. PMID 18550754.
- Laposa RR, Huang EJ, Cleaver JE (2007). "Increased apoptosis, p53 up-regulation, and cerebellar neuronal degeneration in repair-deficient Cockayne syndrome mice". Proc. Natl. Acad. Sci. U.S.A. 104 (4): 1389–94. doi:10.1073/pnas.0610619104. PMC 1783131. PMID 17229834.
- La Spada AR, Morrison RS (2005). "The power of the dark side: Huntington's disease protein and p53 form a deadly alliance". Neuron 47 (1): 1–3. doi:10.1016/j.neuron.2005.06.023. PMID 15996541.
- Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, Forbes MS, Macdonald T, Gaston B (2007). "S-nitrosothiols signal hypoxia-mimetic vascular pathology". J. Clin. Invest. 117 (9): 2592–601. doi:10.1172/JCI29444. PMC 1952618. PMID 17786245.
- "The Overlooked Compound That Saves Lives". Retrieved 8 July 2013. Julius Goepp, MD. Published in Life Extension, May 2010, quote: ". . . the doses they used correspond to a human dose of about 20 grams (20,000 mg) per day."
- Hildebrandt W, Alexander S, Bärtsch P, Dröge W (2002). "Effect of N-acetyl-cysteine on the hypoxic ventilatory response and erythropoietin production: linkage between plasma thiol redox state and O(2) chemosensitivity". Blood 99 (5): 1552–5. doi:10.1182/blood.V99.5.1552. PMID 11861267.
- Wang AL, Wang JP, Wang H, Chen YH, Zhao L, Wang LS, Wei W, Xu DX (2006). "A dual effect of N-acetylcysteine on acute ethanol-induced liver damage in mice". Hepatol. Res. 34 (3): 199–206. doi:10.1016/j.hepres.2005.12.005. PMID 16439183.
- Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (2008). "N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility". Expert Opin Biol Ther 8 (12): 1955–62. doi:10.1517/14728220802517901. PMID 18990082.
- Kupchik YM, Moussawi K, Tang XC, Wang X, Kalivas BC, Kolokithas R, Ogburn KB, Kalivas PW (2012). "The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine". Biol. Psychiatry 71 (11): 978–86. doi:10.1016/j.biopsych.2011.10.024. PMC 3340445. PMID 22137594.
- Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuénod M, Buclin T, Do KQ (2008). "Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients". Neuropsychopharmacology 33 (9): 2187–99. doi:10.1038/sj.npp.1301624. PMID 18004285.
- Garrett CE, Prasad K (2004). "The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions". Advanced Synthesis & Catalysis 346 (8): 889–900. doi:10.1002/adsc.200404071.
- "N-ACETYL-L-CYSTEINE Product Information". Sigma. Sigma-aldrich. Retrieved 9 November 2014.
- Bavarsad Shahripour, R; Harrigan, MR; Alexandrov, AV (Mar 2014). "N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities.". Brain and behavior 4 (2): 108–122. doi:10.1002/brb3.208. PMC 3967529. PMID 24683506.
- Bachert C, Hörmann K, Mösges R, Rasp G, Riechelmann H, Müller R, Luckhaupt H, Stuck BA, Rudack C (2003). "An update on the diagnosis and treatment of sinusitis and nasal polyposis". Allergy 58 (3): 176–91. doi:10.1034/j.1398-9995.2003.02172.x. PMID 12653791.
- Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, Lanzone A (2002). "N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome". Fertil. Steril. 77 (6): 1128–35. doi:10.1016/S0015-0282(02)03133-3. PMID 12057717.
- Aitio ML (2006). "N-acetylcysteine -- passe-partout or much ado about nothing?". Br J Clin Pharmacol 61 (1): 5–15. doi:10.1111/j.1365-2125.2005.02523.x. PMC 1884975. PMID 16390346.
- Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, Dick WC (1974). "Management of the dry eye in Sjogren's syndrome". Br J Ophthalmol 58 (9): 798–805. doi:10.1136/bjo.58.9.798. PMC 1215027. PMID 4433493.
- Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, Sisodiya S (2002). "N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects". Neurology 59 (9): 1447–9. doi:10.1212/wnl.59.9.1447. PMID 12427904. Lay summary – Medscape.
- Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL (2011). "Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis". N. Engl. J. Med. 365 (19): 1781–9. doi:10.1056/NEJMoa1101214. PMID 22070475.
- Martínez-Banaclocha, M. A. (2012). "N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for?". Medical Hypotheses 79 (1): 8–12. doi:10.1016/j.mehy.2012.03.021. PMID 22546753.
- N-Acetylcysteine for Neuroprotection in Parkinson's Disease (NAC for PD)
- Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
- Showell, MG; Brown, J; Yazdani, A; Stankiewicz, MT; Hart, RJ (19 January 2011). "Antioxidants for male subfertility.". The Cochrane database of systematic reviews (1): CD007411. PMID 21249690.